The functional role of miRNAs in inflammatory pathways associated with intestinal epithelial tight junction barrier regulation in IBD

[1] Flynn S, Eisenstein S. Inflammatory bowel disease presentation and diagnosis. Surg Clin North Am. 2019; 99: 1051–1062. FlynnS EisensteinS Inflammatory bowel disease presentation and diagnosis Surg Clin North Am 2019 99 1051 1062 10.1016/j.suc.2019.08.00131676047 Search in Google Scholar

[2] Mak WY, Zhao M, Ng SC, Burisch J. The epidemiology of inflammatory bowel disease: East meets West. J Gastroenterol Hepatol. 2020; 35: 380–389. MakWY ZhaoM NgSC BurischJ The epidemiology of inflammatory bowel disease: East meets West J Gastroenterol Hepatol 2020 35 380 389 10.1111/jgh.1487231596960 Search in Google Scholar

[3] Coward S, Clement F, Benchimol EI, Bernstein CN, Avina-Zubieta JA, Bitton A, Carroll MW, Hazlewood G, Jacobson K, Jelinski S, et al. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterology. 2019; 156: 1345–1353.e4. CowardS ClementF BenchimolEI BernsteinCN Avina-ZubietaJA BittonA CarrollMW HazlewoodG JacobsonK JelinskiS Past and future burden of inflammatory bowel diseases based on modeling of population-based data Gastroenterology 2019 156 1345 1353.e4 10.1053/j.gastro.2019.01.00230639677 Search in Google Scholar

[4] Burisch J, Jess T, Martinato M, Lakatos PL, ECCO -EpiCom. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013; 7: 322–337. BurischJ JessT MartinatoM LakatosPL ECCO -EpiCom The burden of inflammatory bowel disease in Europe J Crohns Colitis 2013 7 322 337 10.1016/j.crohns.2013.01.01023395397 Search in Google Scholar

[5] Ramos GP, Papadakis KA. Mechanisms of disease: Inflammatory bowel diseases. Mayo Clin Proc. 2019; 94: 155–165. RamosGP PapadakisKA Mechanisms of disease: Inflammatory bowel diseases Mayo Clin Proc 2019 94 155 165 10.1016/j.mayocp.2018.09.013638615830611442 Search in Google Scholar

[6] Odenwald MA, Turner JR. The intestinal epithelial barrier: A therapeutic target? Nat Rev Gastroenterol Hepatol. 2017; 14: 9–21. OdenwaldMA TurnerJR The intestinal epithelial barrier: A therapeutic target? Nat Rev Gastroenterol Hepatol 2017 14 9 21 10.1038/nrgastro.2016.169555446827848962 Search in Google Scholar

[7] Vancamelbeke M, Vermeire S. The intestinal barrier: A fundamental role in health and disease. Expert Rev Gastroenterol Hepatol. 2017; 11: 821–834. VancamelbekeM VermeireS The intestinal barrier: A fundamental role in health and disease Expert Rev Gastroenterol Hepatol 2017 11 821 834 10.1080/17474124.2017.1343143610480428650209 Search in Google Scholar

[8] McGuckin MA, Eri R, Simms LA, Florin THJ, Radford-Smith G. Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis. 2009; 15: 100–113. McGuckinMA EriR SimmsLA FlorinTHJ Radford-SmithG Intestinal barrier dysfunction in inflammatory bowel diseases Inflamm Bowel Dis 2009 15 100 113 10.1002/ibd.2053918623167 Search in Google Scholar

[9] Dokladny K, Zuhl MN, Moseley PL. Intestinal epithelial barrier function and tight junction proteins with heat and exercise. J Appl Physiol. 2016; 120: 692–701. DokladnyK ZuhlMN MoseleyPL Intestinal epithelial barrier function and tight junction proteins with heat and exercise J Appl Physiol 2016 120 692 701 10.1152/japplphysiol.00536.2015486837226359485 Search in Google Scholar

[10] Salim SY, Söderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis. 2011; 17: 362–381. SalimSY SöderholmJD Importance of disrupted intestinal barrier in inflammatory bowel diseases Inflamm Bowel Dis 2011 17 362 381 10.1002/ibd.2140320725949 Search in Google Scholar

[11] Michielan A, D’Incà R. Intestinal permeability in inflammatory bowel disease: Pathogenesis, clinical evaluation, and therapy of leaky gut. Mediators Inflamm. 2015; 2015: 628157. MichielanA D’IncàR Intestinal permeability in inflammatory bowel disease: Pathogenesis, clinical evaluation, and therapy of leaky gut Mediators Inflamm 2015 2015 628157 10.1155/2015/628157463710426582965 Search in Google Scholar

[12] Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281–297. BartelDP MicroRNAs: Genomics, biogenesis, mechanism, and function Cell 2004 116 281 297 10.1016/S0092-8674(04)00045-514744438 Search in Google Scholar

[13] Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75: 843–854. LeeRC FeinbaumRL AmbrosV The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 Cell 1993 75 843 854 10.1016/0092-8674(93)90529-Y8252621 Search in Google Scholar

[14] Ambros V. The functions of animal microRNAs. Nature. 2004; 431: 350–355. AmbrosV The functions of animal microRNAs Nature 2004 431 350 355 10.1038/nature0287115372042 Search in Google Scholar

[15] Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science. 2001; 294: 858–862. LauNC LimLP WeinsteinEG BartelDP An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans Science 2001 294 858 862 10.1126/science.106506211679671 Search in Google Scholar

[16] Gu S, Jin L, Zhang F, Sarnow P, Kay MA. Biological basis for restriction of microRNA targets to the 3’ untranslated region in mammalian mRNAs. Nat Struct Mol Biol. 2009; 16: 144–150. GuS JinL ZhangF SarnowP KayMA Biological basis for restriction of microRNA targets to the 3’ untranslated region in mammalian mRNAs Nat Struct Mol Biol 2009 16 144 150 10.1038/nsmb.1552271375019182800 Search in Google Scholar

[17] Baek D, Villén J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature. 2008; 455: 64–71. BaekD VillénJ ShinC CamargoFD GygiSP BartelDP The impact of microRNAs on protein output Nature 2008 455 64 71 10.1038/nature07242274509418668037 Search in Google Scholar

[18] Kozomara A, Birgaoanu M, Griffiths-Jones S. miRBase: From microRNA sequences to function. Nucleic Acids Res. 2019; 47: D155–D162. KozomaraA BirgaoanuM Griffiths-JonesS miRBase: From microRNA sequences to function Nucleic Acids Res 2019 47 D155 D162 10.1093/nar/gky1141632391730423142 Search in Google Scholar

[19] Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science. 2001; 294: 853–858. Lagos-QuintanaM RauhutR LendeckelW TuschlT Identification of novel genes coding for small expressed RNAs Science 2001 294 853 858 10.1126/science.106492111679670 Search in Google Scholar

[20] Lagos-Quintana M, Rauhut R, Meyer J, Borkhardt A, Tuschl T. New microRNAs from mouse and human. RNA. 2003; 9: 175–179. Lagos-QuintanaM RauhutR MeyerJ BorkhardtA TuschlT New microRNAs from mouse and human RNA 2003 9 175 179 10.1261/rna.2146903137038212554859 Search in Google Scholar

[21] Guo L, Zhao Y, Zhang H, Yang S, Chen F. Integrated evolutionary analysis of human miRNA gene clusters and families implicates evolutionary relationships. Gene. 2014; 534: 24–32. GuoL ZhaoY ZhangH YangS ChenF Integrated evolutionary analysis of human miRNA gene clusters and families implicates evolutionary relationships Gene 2014 534 24 32 10.1016/j.gene.2013.10.03724161882 Search in Google Scholar

[22] Baskerville S, Bartel DP. Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes. RNA. 2005; 11: 241–247. BaskervilleS BartelDP Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes RNA 2005 11 241 247 10.1261/rna.7240905137071315701730 Search in Google Scholar

[23] Zhang J, Xu Y, Liu H, Pan Z. MicroRNAs in ovarian follicular atresia and granulosa cell apoptosis. Reprod Biol Endocrinol. 2019; 17: 9. ZhangJ XuY LiuH PanZ MicroRNAs in ovarian follicular atresia and granulosa cell apoptosis Reprod Biol Endocrinol 2019 17 9 10.1186/s12958-018-0450-y632917830630485 Search in Google Scholar

[24] Gan J, Qu Y, Li J, Zhao F, Mu D. An evaluation of the links between microRNA, autophagy, and epilepsy. Rev Neurosci. 2015; 26: 225–237. GanJ QuY LiJ ZhaoF MuD An evaluation of the links between microRNA, autophagy, and epilepsy Rev Neurosci 2015 26 225 237 10.1515/revneuro-2014-006225719305 Search in Google Scholar

[25] Shin VY, Chu K-M. MiRNA as potential biomarkers and therapeutic targets for gastric cancer. World J Gastroenterol. 2014; 20: 10432–10439. ShinVY ChuK-M MiRNA as potential biomarkers and therapeutic targets for gastric cancer World J Gastroenterol 2014 20 10432 10439 10.3748/wjg.v20.i30.10432413085025132759 Search in Google Scholar

[26] Zhou L, Feng Y, Dai J, Ouyang J. Research progress of miRNA regulation in differentiation of adipose-derived stem cells. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi Zhongguo Xiufu Chongjian Waike Zazhi Chin J Reparative Reconstr Surg. 2017; 31: 1506–1511. ZhouL FengY DaiJ OuyangJ Research progress of miRNA regulation in differentiation of adipose-derived stem cells Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi Zhongguo Xiufu Chongjian Waike Zazhi Chin J Reparative Reconstr Surg 2017 31 1506 1511 Search in Google Scholar

[27] Wu W, He C, Liu C, Cao AT, Xue X, Evans-Marin HL, Sun M, Fang L, Yao S, Pinchuk IV, et al. miR-10a inhibits dendritic cell activation and Th1/Th17 cell immune responses in IBD. Gut. 2015; 64: 1755–1764. WuW HeC LiuC CaoAT XueX Evans-MarinHL SunM FangL YaoS PinchukIV miR-10a inhibits dendritic cell activation and Th1/Th17 cell immune responses in IBD Gut 2015 64 1755 1764 10.1136/gutjnl-2014-30798025281418 Search in Google Scholar

[28] Li M, Zhang S, Qiu Y, He Y, Chen B, Mao R, Cui Y, Zeng Z, Chen M. Up-regulation of miR-665 promotes apoptosis and colitis in inflammatory bowel disease by repressing the endoplasmic reticulum stress components XBP1 and ORMDL3. Cell Death Dis. 2017; 8: e2699. LiM ZhangS QiuY HeY ChenB MaoR CuiY ZengZ ChenM Up-regulation of miR-665 promotes apoptosis and colitis in inflammatory bowel disease by repressing the endoplasmic reticulum stress components XBP1 and ORMDL3 Cell Death Dis 2017 8 e2699 10.1038/cddis.2017.76538656928333149 Search in Google Scholar

[29] Lee EG, Boone DL, Chai S, Libby SL, Chien M, Lodolce JP, Ma A. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science. 2000; 289: 2350–2354. LeeEG BooneDL ChaiS LibbySL ChienM LodolceJP MaA Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice Science 2000 289 2350 2354 10.1126/science.289.5488.2350358239911009421 Search in Google Scholar

[30] Ma A, Malynn BA. A20: Linking a complex regulator of ubiquitylation to immunity and human disease. Nat Rev Immunol. 2012; 12: 774–785. MaA MalynnBA A20: Linking a complex regulator of ubiquitylation to immunity and human disease Nat Rev Immunol 2012 12 774 785 10.1038/nri3313358239723059429 Search in Google Scholar

[31] Shembade N, Harhaj EW. Regulation of NF-κB signaling by the A20 deubiquitinase. Cell Mol Immunol. 2012; 9: 123–130. ShembadeN HarhajEW Regulation of NF-κB signaling by the A20 deubiquitinase Cell Mol Immunol 2012 9 123 130 10.1038/cmi.2011.59353205022343828 Search in Google Scholar

[32] Kolodziej LE, Lodolce JP, Chang JE, Schneider JR, Grimm WA, Bartulis SJ, Zhu X, Messer JS, Murphy SF, Reddy N, et al. TNFAIP3 maintains intestinal barrier function and supports epithelial cell tight junctions. PLoS One. 2011; 6: e26352. KolodziejLE LodolceJP ChangJE SchneiderJR GrimmWA BartulisSJ ZhuX MesserJS MurphySF ReddyN TNFAIP3 maintains intestinal barrier function and supports epithelial cell tight junctions PLoS One 2011 6 e26352 10.1371/journal.pone.0026352319877522031828 Search in Google Scholar

[33] Felwick RK, Dingley GJR, Martinez-Nunez R, Sanchez-Elsner T, Cummings JRF, Collins JE. MicroRNA23a overexpression in Crohn's disease targets tumour necrosis factor alpha inhibitor protein 3, increasing sensitivity to TNF and modifying the epithelial barrier. J Crohns Colitis. 2020; 14: 381–392. FelwickRK DingleyGJR Martinez-NunezR Sanchez-ElsnerT CummingsJRF CollinsJE MicroRNA23a overexpression in Crohn's disease targets tumour necrosis factor alpha inhibitor protein 3, increasing sensitivity to TNF and modifying the epithelial barrier J Crohns Colitis 2020 14 381 392 10.1093/ecco-jcc/jjz14531626694 Search in Google Scholar

[34] Roman BL, Hinck AP. ALK1 signaling in development and disease: new paradigms. Cell Mol Life Sci. 2017; 74: 4539–4560. RomanBL HinckAP ALK1 signaling in development and disease: new paradigms Cell Mol Life Sci 2017 74 4539 4560 10.1007/s00018-017-2636-4568706928871312 Search in Google Scholar

[35] Ihara S, Hirata Y, Koike K. TGF-β in inflammatory bowel disease: A key regulator of immune cells, epithelium, and the intestinal microbiota. J Gastroenterol. 2017; 52: 777–787. IharaS HirataY KoikeK TGF-β in inflammatory bowel disease: A key regulator of immune cells, epithelium, and the intestinal microbiota J Gastroenterol 2017 52 777 787 10.1007/s00535-017-1350-128534191 Search in Google Scholar

[36] Bidart M, Ricard N, Levet S, Samson M, Mallet C, David L, Subileau M, Tillet E, Feige J-J, Bailly S. BMP9 is produced by hepatocytes and circulates mainly in an active mature form complexed to its prodomain. Cell Mol Life Sci. 2012; 69: 313–324. BidartM RicardN LevetS SamsonM MalletC DavidL SubileauM TilletE FeigeJ-J BaillyS BMP9 is produced by hepatocytes and circulates mainly in an active mature form complexed to its prodomain Cell Mol Life Sci 2012 69 313 324 10.1007/s00018-011-0751-121710321 Search in Google Scholar

[37] Neuhaus H, Rosen V, Thies RS. Heart specific expression of mouse BMP-10 a novel member of the TGF-beta superfamily. Mech Dev. 1999; 80: 181–184. NeuhausH RosenV ThiesRS Heart specific expression of mouse BMP-10 a novel member of the TGF-beta superfamily Mech Dev 1999 80 181 184 10.1016/S0925-4773(98)00221-4 Search in Google Scholar

[38] Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015; 347: 1260419. UhlénM FagerbergL HallströmBM LindskogC OksvoldP MardinogluA SivertssonÅ KampfC SjöstedtE AsplundA Proteomics. Tissue-based map of the human proteome Science 2015 347 1260419 10.1126/science.126041925613900 Search in Google Scholar

[39] Toyonaga T, Steinbach EC, Keith BP, Barrow JB, Schaner MR, Wolber EA, Beasley C, Huling J, Wang Y, Allbritton NL, et al. Decreased colonic activin receptor-like kinase 1 disrupts epithelial barrier integrity in patients with Crohn's disease. Cell Mol Gastroenterol Hepatol. 2020; 10: 779–796. ToyonagaT SteinbachEC KeithBP BarrowJB SchanerMR WolberEA BeasleyC HulingJ WangY AllbrittonNL Decreased colonic activin receptor-like kinase 1 disrupts epithelial barrier integrity in patients with Crohn's disease Cell Mol Gastroenterol Hepatol 2020 10 779 796 10.1016/j.jcmgh.2020.06.005750256632561494 Search in Google Scholar

[40] Jiang YJ, Bikle DD. LncRNA profiling reveals new mechanism for VDR protection against skin cancer formation. J Steroid Biochem Mol Biol. 2014; 144, Pt A: 87–90. JiangYJ BikleDD LncRNA profiling reveals new mechanism for VDR protection against skin cancer formation J Steroid Biochem Mol Biol 2014 144 Pt A 87 90 10.1016/j.jsbmb.2013.11.01824342142 Search in Google Scholar

[41] Raveh E, Matouk IJ, Gilon M, Hochberg A. The H19 Long non-coding RNA in cancer initiation, progression and metastasis - a proposed unifying theory. Mol Cancer. 2015; 14: 184. RavehE MatoukIJ GilonM HochbergA The H19 Long non-coding RNA in cancer initiation, progression and metastasis - a proposed unifying theory Mol Cancer 2015 14 184 10.1186/s12943-015-0458-2463268826536864 Search in Google Scholar

[42] Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, Dominguez CE, Jurutka PW. The nuclear vitamin D receptor: Biological and molecular regulatory properties revealed. J Bone Miner Res. 1998; 13: 325–349. HausslerMR WhitfieldGK HausslerCA HsiehJC ThompsonPD SelznickSH DominguezCE JurutkaPW The nuclear vitamin D receptor: Biological and molecular regulatory properties revealed J Bone Miner Res 1998 13 325 349 10.1359/jbmr.1998.13.3.3259525333 Search in Google Scholar

[43] Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, Luderer HF, Lieben L, Mathieu C, Demay M. Vitamin D and human health: Lessons from vitamin D receptor null mice. Endocr Rev. 2008; 29: 726–776. BouillonR CarmelietG VerlindenL van EttenE VerstuyfA LudererHF LiebenL MathieuC DemayM Vitamin D and human health: Lessons from vitamin D receptor null mice Endocr Rev 2008 29 726 776 10.1210/er.2008-0004258338818694980 Search in Google Scholar

[44] Mousa A, Misso M, Teede H, Scragg R, de Courten B. Effect of vitamin D supplementation on inflammation: protocol for a systematic review. BMJ Open. 2016; 6: e010804. MousaA MissoM TeedeH ScraggR de CourtenB Effect of vitamin D supplementation on inflammation: protocol for a systematic review BMJ Open 2016 6 e010804 10.1136/bmjopen-2015-010804482345627048637 Search in Google Scholar

[45] Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014; 14: 342–357. FeldmanD KrishnanAV SwamiS GiovannucciE FeldmanBJ The role of vitamin D in reducing cancer risk and progression Nat Rev Cancer 2014 14 342 357 10.1038/nrc369124705652 Search in Google Scholar

[46] Liu W, Chen Y, Golan MA, Annunziata ML, Du J, Dougherty U, Kong J, Musch M, Huang Y, Pekow J, et al. Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis. J Clin Invest. 2013; 123: 3983–3996. LiuW ChenY GolanMA AnnunziataML DuJ DoughertyU KongJ MuschM HuangY PekowJ Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis J Clin Invest 2013 123 3983 3996 10.1172/JCI65842375424123945234 Search in Google Scholar

[47] Wang L, Wang ZT, Hu JJ, Fan R, Zhou J, Zhong J. Polymorphisms of the vitamin D receptor gene and the risk of inflammatory bowel disease: a meta–analysis. Genet Mol Res. 2014; 13: 2598–2610. WangL WangZT HuJJ FanR ZhouJ ZhongJ Polymorphisms of the vitamin D receptor gene and the risk of inflammatory bowel disease: a meta–analysis Genet Mol Res 2014 13 2598 2610 10.4238/2014.April.8.224782048 Search in Google Scholar

[48] Du J, Chen Y, Shi Y, Liu T, Cao Y, Tang Y, Ge X, Nie H, Zheng C, Li YC. 1,25-Dihydroxyvitamin D protects intestinal epithelial barrier by regulating the myosin light chain kinase signaling pathway. Inflamm Bowel Dis. 2015; 21: 2495–2506. DuJ ChenY ShiY LiuT CaoY TangY GeX NieH ZhengC LiYC 1,25-Dihydroxyvitamin D protects intestinal epithelial barrier by regulating the myosin light chain kinase signaling pathway Inflamm Bowel Dis 2015 21 2495 2506 10.1097/MIB.0000000000000526464641426287999 Search in Google Scholar

[49] Chen S, Zhu J, Chen G, Zuo S, Zhang J, Chen Z, Wang X, Li J, Liu Y, Wang P. 1,25-Dihydroxyvitamin D3 preserves intestinal epithelial barrier function from TNF-α induced injury via suppression of NF-kB p65 mediated MLCK-P-MLC signaling pathway. Biochem Biophys Res Commun. 2015; 460: 873–878. ChenS ZhuJ ChenG ZuoS ZhangJ ChenZ WangX LiJ LiuY WangP 1,25-Dihydroxyvitamin D3 preserves intestinal epithelial barrier function from TNF-α induced injury via suppression of NF-kB p65 mediated MLCK-P-MLC signaling pathway Biochem Biophys Res Commun 2015 460 873 878 10.1016/j.bbrc.2015.03.12525838204 Search in Google Scholar

[50] Chen S-W, Wang P-Y, Zhu J, Chen G-W, Zhang J-L, Chen Z-Y, Zuo S, Liu Y-C, Pan Y-S. Protective effect of 1,25-dihydroxyvitamin d3 on lipopolysaccharide-induced intestinal epithelial tight junction injury in caco-2 cell monolayers. Inflammation. 2015; 38: 375–383. ChenS-W WangP-Y ZhuJ ChenG-W ZhangJ-L ChenZ-Y ZuoS LiuY-C PanY-S Protective effect of 1,25-dihydroxyvitamin d3 on lipopolysaccharide-induced intestinal epithelial tight junction injury in caco-2 cell monolayers Inflammation 2015 38 375 383 10.1007/s10753-014-0041-925344656 Search in Google Scholar

[51] Zhao H, Zhang H, Wu H, Li H, Liu L, Guo J, Li C, Shih DQ, Zhang X. Protective role of 1,25(OH)2 vitamin D3 in the mucosal injury and epithelial barrier disruption in DSS-induced acute colitis in mice. BMC Gastroenterol. 2012; 12: 57. ZhaoH ZhangH WuH LiH LiuL GuoJ LiC ShihDQ ZhangX Protective role of 1,25(OH)2 vitamin D3 in the mucosal injury and epithelial barrier disruption in DSS-induced acute colitis in mice BMC Gastroenterol 2012 12 57 10.1186/1471-230X-12-57346461422647055 Search in Google Scholar

[52] Chen S-W, Wang P-Y, Liu Y-C, Sun L, Zhu J, Zuo S, Ma J, Li T-Y, Zhang J-L, Chen G-W, et al. Effect of long noncoding RNA H19 overexpression on intestinal barrier function and its potential role in the pathogenesis of ulcerative colitis. Inflamm Bowel Dis. 2016; 22: 2582–2592. ChenS-W WangP-Y LiuY-C SunL ZhuJ ZuoS MaJ LiT-Y ZhangJ-L ChenG-W Effect of long noncoding RNA H19 overexpression on intestinal barrier function and its potential role in the pathogenesis of ulcerative colitis Inflamm Bowel Dis 2016 22 2582 2592 10.1097/MIB.000000000000093227661667 Search in Google Scholar

[53] Matouk IJ, Halle D, Raveh E, Gilon M, Sorin V, Hochberg A. The role of the oncofetal H19 lncRNA in tumor metastasis: Orchestrating the EMT-MET decision. Oncotarget. 2016; 7: 3748–3765. MatoukIJ HalleD RavehE GilonM SorinV HochbergA The role of the oncofetal H19 lncRNA in tumor metastasis: Orchestrating the EMT-MET decision Oncotarget 2016 7 3748 3765 10.18632/oncotarget.6387482616726623562 Search in Google Scholar

[54] Lamas B, Natividad JM, Sokol H. Aryl hydrocarbon receptor and intestinal immunity. Mucosal Immunol. 2018; 11: 1024–1038. LamasB NatividadJM SokolH Aryl hydrocarbon receptor and intestinal immunity Mucosal Immunol 2018 11 1024 1038 10.1038/s41385-018-0019-229626198 Search in Google Scholar

[55] Han B, Sheng B, Zhang Z, Pu A, Yin J, Wang Q, Yang K, Sun L, Yu M, Qiu Y, et al. Aryl hydrocarbon receptor activation in intestinal obstruction ameliorates intestinal barrier dysfunction via suppression of MLCK-MLC phosphorylation pathway. Shock. 2016; 46: 319–328. HanB ShengB ZhangZ PuA YinJ WangQ YangK SunL YuM QiuY Aryl hydrocarbon receptor activation in intestinal obstruction ameliorates intestinal barrier dysfunction via suppression of MLCK-MLC phosphorylation pathway Shock 2016 46 319 328 10.1097/SHK.000000000000059426939041 Search in Google Scholar

[56] Yu M, Wang Q, Ma Y, Li L, Yu K, Zhang Z, Chen G, Li X, Xiao W, Xu P, et al. Aryl hydrocarbon receptor activation modulates intestinal epithelial barrier function by maintaining tight junction integrity. Int J Biol Sci. 2018; 14: 69–77. YuM WangQ MaY LiL YuK ZhangZ ChenG LiX XiaoW XuP Aryl hydrocarbon receptor activation modulates intestinal epithelial barrier function by maintaining tight junction integrity Int J Biol Sci 2018 14 69 77 10.7150/ijbs.22259582105029483826 Search in Google Scholar

[57] Monteleone I, Rizzo A, Sarra M, Sica G, Sileri P, Biancone L, MacDonald TT, Pallone F, Monteleone G. Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology. 2011; 141: 237–248. MonteleoneI RizzoA SarraM SicaG SileriP BianconeL MacDonaldTT PalloneF MonteleoneG Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract Gastroenterology 2011 141 237 248 10.1053/j.gastro.2011.04.00721600206 Search in Google Scholar

[58] Zhao X, Li J, Ma J, Jiao C, Qiu X, Cui X, Wang D, Zhang H. MiR-124a mediates the impairment of intestinal epithelial integrity by targeting aryl hydrocarbon receptor in Crohn's disease. Inflammation. 2020; 43: 1862–1875. ZhaoX LiJ MaJ JiaoC QiuX CuiX WangD ZhangH MiR-124a mediates the impairment of intestinal epithelial integrity by targeting aryl hydrocarbon receptor in Crohn's disease Inflammation 2020 43 1862 1875 10.1007/s10753-020-01259-032607693 Search in Google Scholar

[59] Al Nabhani Z, Montcuquet N, Roy M, Dussaillant M, Hugot J-P, Barreau F. Complementary roles of Nod2 in hematopoietic and nonhematopoietic cells in preventing gut barrier dysfunction dependent on MLCK activity. Inflamm Bowel Dis. 2017; 23: 1109–1119. Al NabhaniZ MontcuquetN RoyM DussaillantM HugotJ-P BarreauF Complementary roles of Nod2 in hematopoietic and nonhematopoietic cells in preventing gut barrier dysfunction dependent on MLCK activity Inflamm Bowel Dis 2017 23 1109 1119 10.1097/MIB.000000000000113528520587 Search in Google Scholar

[60] Su L, Nalle SC, Shen L, Turner ES, Singh G, Breskin LA, Khramtsova EA, Khramtsova G, Tsai P-Y, Fu Y-X, et al. TNFR2 activates MLCK-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis. Gastroenterology. 2013; 145: 407–415. SuL NalleSC ShenL TurnerES SinghG BreskinLA KhramtsovaEA KhramtsovaG TsaiP-Y FuY-X TNFR2 activates MLCK-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis Gastroenterology 2013 145 407 415 10.1053/j.gastro.2013.04.011372228423619146 Search in Google Scholar

[61] Nissan A, Stojadinovic A, Mitrani-Rosenbaum S, Halle D, Grinbaum R, Roistacher M, Bochem A, Dayanc BE, Ritter G, Gomceli I, et al. Colon cancer associated transcript-1: a novel RNA expressed in malignant and pre-malignant human tissues. Int J Cancer. 2012; 130: 1598–1606. NissanA StojadinovicA Mitrani-RosenbaumS HalleD GrinbaumR RoistacherM BochemA DayancBE RitterG GomceliI Colon cancer associated transcript-1: a novel RNA expressed in malignant and pre-malignant human tissues Int J Cancer 2012 130 1598 1606 10.1002/ijc.2617021547902 Search in Google Scholar

[62] Zhang Z, Xie H, Liang D, Huang L, Liang F, Qi Q, Yang X. Long non-coding RNA CCAT1 as a diagnostic and prognostic molecular marker in various cancers: a meta-analysis. Oncotarget. 2018; 9: 23695–23703. ZhangZ XieH LiangD HuangL LiangF QiQ YangX Long non-coding RNA CCAT1 as a diagnostic and prognostic molecular marker in various cancers: a meta-analysis Oncotarget 2018 9 23695 23703 10.18632/oncotarget.24923595511429805767 Search in Google Scholar

[63] Ma D, Cao Y, Wang Z, He J, Chen H, Xiong H, Ren L, Shen C, Zhang X, Yan Y, et al. CCAT1 lncRNA promotes inflammatory bowel disease malignancy by destroying intestinal barrier via downregulating miR-185-3p. Inflamm Bowel Dis. 2019; 25: 862–874. MaD CaoY WangZ HeJ ChenH XiongH RenL ShenC ZhangX YanY CCAT1 lncRNA promotes inflammatory bowel disease malignancy by destroying intestinal barrier via downregulating miR-185-3p Inflamm Bowel Dis 2019 25 862 874 10.1093/ibd/izy38130615124 Search in Google Scholar

[64] Shen Y, Zhou M, Yan J, Gong Z, Xiao Y, Zhang C, Du P, Chen Y. miR-200b inhibits TNF-α-induced IL-8 secretion and tight junction disruption of intestinal epithelial cells in vitro. Am J Physiol Gastrointest Liver Physiol. 2017; 312: G123–G132. ShenY ZhouM YanJ GongZ XiaoY ZhangC DuP ChenY miR-200b inhibits TNF-α-induced IL-8 secretion and tight junction disruption of intestinal epithelial cells in vitro Am J Physiol Gastrointest Liver Physiol 2017 312 G123 G132 10.1152/ajpgi.00316.201627979826 Search in Google Scholar

[65] Gerlach K, McKenzie AN, Neurath MF, Weigmann B. IL-9 regulates intestinal barrier function in experimental T cell-mediated colitis. Tissue Barriers. 2015; 3: e983777. GerlachK McKenzieAN NeurathMF WeigmannB IL-9 regulates intestinal barrier function in experimental T cell-mediated colitis Tissue Barriers 2015 3 e983777 10.4161/21688370.2014.983777437201825838986 Search in Google Scholar

[66] Yuan A, Yang H, Qi H, Cui J, Hua W, Li C, Pang Z, Zheng W, Cui G. IL-9 antibody injection suppresses the inflammation in colitis mice. Biochem Biophys Res Commun. 2015; 468: 921–926. YuanA YangH QiH CuiJ HuaW LiC PangZ ZhengW CuiG IL-9 antibody injection suppresses the inflammation in colitis mice Biochem Biophys Res Commun 2015 468 921 926 10.1016/j.bbrc.2015.11.05726603936 Search in Google Scholar

[67] Nalleweg N, Chiriac MT, Podstawa E, Lehmann C, Rau TT, Atreya R, Krauss E, Hundorfean G, Fichtner-Feigl S, Hartmann A, et al. IL-9 and its receptor are predominantly involved in the pathogenesis of UC. Gut. 2015; 64: 743–755. NallewegN ChiriacMT PodstawaE LehmannC RauTT AtreyaR KraussE HundorfeanG Fichtner-FeiglS HartmannA IL-9 and its receptor are predominantly involved in the pathogenesis of UC Gut 2015 64 743 755 10.1136/gutjnl-2013-30594724957265 Search in Google Scholar

[68] Wang H, Chao K, Ng SC, Bai AH, Yu Q, Yu J, Li M, Cui Y, Chen M, Hu J-F, et al. Pro-inflammatory miR-223 mediates the cross-talk between the IL23 pathway and the intestinal barrier in inflammatory bowel disease. Genome Biol. 2016; 17: 58. WangH ChaoK NgSC BaiAH YuQ YuJ LiM CuiY ChenM HuJ-F Pro-inflammatory miR-223 mediates the cross-talk between the IL23 pathway and the intestinal barrier in inflammatory bowel disease Genome Biol 2016 17 58 10.1186/s13059-016-0901-8481527127029486 Search in Google Scholar

[69] Zeissig S, Bürgel N, Günzel D, Richter J, Mankertz J, Wahnschaffe U, Kroesen AJ, Zeitz M, Fromm M, Schulzke J-D. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut. 2007; 56: 61–72. ZeissigS BürgelN GünzelD RichterJ MankertzJ WahnschaffeU KroesenAJ ZeitzM FrommM SchulzkeJ-D Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease Gut 2007 56 61 72 10.1136/gut.2006.094375185667716822808 Search in Google Scholar

[70] Clark PM, Dawany N, Dampier W, Byers SW, Pestell RG, Tozeren A. Bioinformatics analysis reveals transcriptome and microRNA signatures and drug repositioning targets for IBD and other autoimmune diseases. Inflamm Bowel Dis. 2012; 18: 2315–2333. ClarkPM DawanyN DampierW ByersSW PestellRG TozerenA Bioinformatics analysis reveals transcriptome and microRNA signatures and drug repositioning targets for IBD and other autoimmune diseases Inflamm Bowel Dis 2012 18 2315 2333 10.1002/ibd.2295822488912 Search in Google Scholar

[71] Li L, Huang S, Wang H, Chao K, Ding L, Feng R, Qiu Y, Feng T, Zhou G, Hu J-F, et al. Cytokine IL9 triggers the pathogenesis of inflammatory bowel disease through the miR21-CLDN8 pathway. Inflamm Bowel Dis. 2018; 24: 2211–2223. LiL HuangS WangH ChaoK DingL FengR QiuY FengT ZhouG HuJ-F Cytokine IL9 triggers the pathogenesis of inflammatory bowel disease through the miR21-CLDN8 pathway Inflamm Bowel Dis 2018 24 2211 2223 10.1093/ibd/izy18729788092 Search in Google Scholar

[72] Elson CO, Cong Y, Weaver CT, Schoeb TR, McClanahan TK, Fick RB, Kastelein RA. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology. 2007; 132: 2359–2370. ElsonCO CongY WeaverCT SchoebTR McClanahanTK FickRB KasteleinRA Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice Gastroenterology 2007 132 2359 2370 10.1053/j.gastro.2007.03.10417570211 Search in Google Scholar

[73] Chao K, Zhang S, Yao J, He Y, Chen B, Zeng Z, Zhong B, Chen M. Imbalances of CD4(+) T-cell subgroups in Crohn's disease and their relationship with disease activity and prognosis. J Gastroenterol Hepatol. 2014; 29: 1808–1814. ChaoK ZhangS YaoJ HeY ChenB ZengZ ZhongB ChenM Imbalances of CD4(+) T-cell subgroups in Crohn's disease and their relationship with disease activity and prognosis J Gastroenterol Hepatol 2014 29 1808 1814 10.1111/jgh.1259224720272 Search in Google Scholar

[74] Faghih M, Rostami-Nejad M, Amani D, Sadeghi A, Pourhoseingholi MA, Masotti A, Zali MR. Analysis of IL17A and IL21 expression in the small intestine of celiac disease patients and correlation with circulating thioredoxin level. Genet Test Mol Biomark. 2018; 22: 518–525. FaghihM Rostami-NejadM AmaniD SadeghiA PourhoseingholiMA MasottiA ZaliMR Analysis of IL17A and IL21 expression in the small intestine of celiac disease patients and correlation with circulating thioredoxin level Genet Test Mol Biomark 2018 22 518 525 10.1089/gtmb.2018.012830183349 Search in Google Scholar

[75] Caielli S, Veiga DT, Balasubramanian P, Athale S, Domic B, Murat E, Banchereau R, Xu Z, Chandra M, Chung C-H, et al. A CD4+ T cell population expanded in lupus blood provides B cell help through interleukin-10 and succinate. Nat Med. 2019; 25: 75–81. CaielliS VeigaDT BalasubramanianP AthaleS DomicB MuratE BanchereauR XuZ ChandraM ChungC-H A CD4+ T cell population expanded in lupus blood provides B cell help through interleukin-10 and succinate Nat Med 2019 25 75 81 10.1038/s41591-018-0254-9632501230478422 Search in Google Scholar

[76] Qiu L, Yu Q, Zhou Y, Zheng S, Tao J, Jiang Q, Yuan G. Functionally impaired follicular helper T cells induce regulatory B cells and CD14+ human leukocyte antigen-DR- cell differentiation in non-small cell lung cancer. Cancer Sci. 2018; 109: 3751–3761. QiuL YuQ ZhouY ZhengS TaoJ JiangQ YuanG Functionally impaired follicular helper T cells induce regulatory B cells and CD14+ human leukocyte antigen-DR- cell differentiation in non-small cell lung cancer Cancer Sci 2018 109 3751 3761 10.1111/cas.13836627209030325558 Search in Google Scholar

[77] Wang M, Guo J, Zhao Y-Q, Wang J-P. IL-21 mediates microRNA-423-5p/claudin-5 signal pathway and intestinal barrier function in inflammatory bowel disease. Aging. 2020; 12: 16099–16110. WangM GuoJ ZhaoY-Q WangJ-P IL-21 mediates microRNA-423-5p/claudin-5 signal pathway and intestinal barrier function in inflammatory bowel disease Aging 2020 12 16099 16110 10.18632/aging.103566748573932855360 Search in Google Scholar

[78] Ligumsky M, Simon PL, Karmeli F, Rachmilewitz D. Role of interleukin 1 in inflammatory bowel disease - enhanced production during active disease. Gut. 1990; 31: 686–689. LigumskyM SimonPL KarmeliF RachmilewitzD Role of interleukin 1 in inflammatory bowel disease - enhanced production during active disease Gut 1990 31 686 689 10.1136/gut.31.6.68613784972379873 Search in Google Scholar

[79] Al-Sadi RM, Ma TY. IL-1beta causes an increase in intestinal epithelial tight junction permeability. J Immunol. 2007; 178: 4641–4649. Al-SadiRM MaTY IL-1beta causes an increase in intestinal epithelial tight junction permeability J Immunol 2007 178 4641 4649 10.4049/jimmunol.178.7.4641372422117372023 Search in Google Scholar

[80] Al-Sadi R, Guo S, Dokladny K, Smith MA, Ye D, Kaza A, Watterson DM, Ma TY. Mechanism of interleukin-1β induced-increase in mouse intestinal permeability in vivo. J Interferon Cytokine Res. 2012; 32: 474–484. Al-SadiR GuoS DokladnyK SmithMA YeD KazaA WattersonDM MaTY Mechanism of interleukin-1β induced-increase in mouse intestinal permeability in vivo J Interferon Cytokine Res 2012 32 474 484 10.1089/jir.2012.0031346407122817402 Search in Google Scholar

[81] Rawat M, Nighot M, Al-Sadi R, Gupta Y, Viszwapriya D, Yochum G, Koltun W, Ma TY. IL1B increases intestinal tight junction permeability by up-regulation of MIR200C-3p, which degrades occludin mRNA. Gastroenterology. 2020; 159: 1375–1389. RawatM NighotM Al-SadiR GuptaY ViszwapriyaD YochumG KoltunW MaTY IL1B increases intestinal tight junction permeability by up-regulation of MIR200C-3p, which degrades occludin mRNA Gastroenterology 2020 159 1375 1389 10.1053/j.gastro.2020.06.03832569770 Search in Google Scholar

[82] Ye D, Guo S, Al-Sadi R, Ma TY. MicroRNA regulation of intestinal epithelial tight junction permeability. Gastroenterology. 2011; 141: 1323–1333. YeD GuoS Al-SadiR MaTY MicroRNA regulation of intestinal epithelial tight junction permeability Gastroenterology 2011 141 1323 1333 10.1053/j.gastro.2011.07.005372421721763238 Search in Google Scholar

[83] Yuniati L, Scheijen B, van der Meer LT, van Leeuwen FN. Tumor suppressors BTG1 and BTG2: Beyond growth control. J Cell Physiol. 2019; 234: 5379–5389. YuniatiL ScheijenB van der MeerLT van LeeuwenFN Tumor suppressors BTG1 and BTG2: Beyond growth control J Cell Physiol 2019 234 5379 5389 10.1002/jcp.27407658753630350856 Search in Google Scholar

[84] He C, Shi Y, Wu R, Sun M, Fang L, Wu W, Liu C, Tang M, Li Z, Wang P, et al. miR-301a promotes intestinal mucosal inflammation through induction of IL-17A and TNF-α in IBD. Gut 2016; 65: 1938–1950. HeC ShiY WuR SunM FangL WuW LiuC TangM LiZ WangP miR-301a promotes intestinal mucosal inflammation through induction of IL-17A and TNF-α in IBD Gut 2016 65 1938 1950 10.1136/gutjnl-2015-30938926338824 Search in Google Scholar

[85] Lu Z, Li Y, Takwi A, Li B, Zhang J, Conklin DJ, Young KH, Martin R, Li Y. miR-301a as an NF-κB activator in pancreatic cancer cells. EMBO J. 2011; 30: 57–67. LuZ LiY TakwiA LiB ZhangJ ConklinDJ YoungKH MartinR LiY miR-301a as an NF-κB activator in pancreatic cancer cells EMBO J 2011 30 57 67 10.1038/emboj.2010.296302011621113131 Search in Google Scholar

[86] He C, Yu T, Shi Y, Ma C, Yang W, Fang L, Sun M, Wu W, Xiao F, Guo F, et al. MicroRNA 301A promotes intestinal inflammation and colitis-associated cancer development by inhibiting BTG1. Gastroenterology. 2017; 152: 1434–1448. HeC YuT ShiY MaC YangW FangL SunM WuW XiaoF GuoF MicroRNA 301A promotes intestinal inflammation and colitis-associated cancer development by inhibiting BTG1 Gastroenterology 2017 152 1434 1448 10.1053/j.gastro.2017.01.04928193514 Search in Google Scholar

[87] Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994; 264: 1415–1421. DarnellJE KerrIM StarkGR Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins Science 1994 264 1415 1421 10.1126/science.81974558197455 Search in Google Scholar

[88] Li Y, de Haar C, Chen M, Deuring J, Gerrits MM, Smits R, Xia B, Kuipers EJ, van der Woude CJ. Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut. 2010; 59: 227–235. LiY de HaarC ChenM DeuringJ GerritsMM SmitsR XiaB KuipersEJ van der WoudeCJ Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis Gut 2010 59 227 235 10.1136/gut.2009.18417619926618 Search in Google Scholar

[89] Koukos G, Polytarchou C, Kaplan JL, Morley-Fletcher A, Gras-Miralles B, Kokkotou E, Baril-Dore M, Pothoulakis C, Winter HS, Iliopoulos D. MicroRNA-124 regulates STAT3 expression and is down-regulated in colon tissues of pediatric patients with ulcerative colitis. Gastroenterology. 2013; 145: 842–852.e2. KoukosG PolytarchouC KaplanJL Morley-FletcherA Gras-MirallesB KokkotouE Baril-DoreM PothoulakisC WinterHS IliopoulosD MicroRNA-124 regulates STAT3 expression and is down-regulated in colon tissues of pediatric patients with ulcerative colitis Gastroenterology 2013 145 842 852.e2 10.1053/j.gastro.2013.07.001442705823856509 Search in Google Scholar

[90] Chu X-Q, Wang J, Chen G-X, Zhang G-Q, Zhang D-Y, Cai Y-Y. Overexpression of microRNA-495 improves the intestinal mucosal barrier function by targeting STAT3 via inhibition of the JAK/STAT3 signaling pathway in a mouse model of ulcerative colitis. Pathol Res Pract. 2018; 214: 151–162. ChuX-Q WangJ ChenG-X ZhangG-Q ZhangD-Y CaiY-Y Overexpression of microRNA-495 improves the intestinal mucosal barrier function by targeting STAT3 via inhibition of the JAK/STAT3 signaling pathway in a mouse model of ulcerative colitis Pathol Res Pract 2018 214 151 162 10.1016/j.prp.2017.10.00329129493 Search in Google Scholar

[91] Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004; 59: 21–26. HerbstRS Review of epidermal growth factor receptor biology Int J Radiat Oncol Biol Phys 2004 59 21 26 10.1016/j.ijrobp.2003.11.04115142631 Search in Google Scholar

[92] Zhang B, Tian Y, Jiang P, Jiang Y, Li C, Liu T, Zhou R, Yang N, Zhou X, Liu Z. MicroRNA-122a regulates zonulin by targeting EGFR in intestinal epithelial dysfunction. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2017; 42: 848–858. ZhangB TianY JiangP JiangY LiC LiuT ZhouR YangN ZhouX LiuZ MicroRNA-122a regulates zonulin by targeting EGFR in intestinal epithelial dysfunction Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 2017 42 848 858 10.1159/00047862928641303 Search in Google Scholar

[93] Liu Z-H, Huang M-J, Zhang X-W, Wang L, Huang N-Q, Peng H, Lan P, Peng J-S, Yang Z, Xia Y, et al. The effects of perioperative probiotic treatment on serum zonulin concentration and subsequent postoperative infectious complications after colorectal cancer surgery: a double-center and double-blind randomized clinical trial. Am J Clin Nutr. 2013; 97: 117–126. LiuZ-H HuangM-J ZhangX-W WangL HuangN-Q PengH LanP PengJ-S YangZ XiaY The effects of perioperative probiotic treatment on serum zonulin concentration and subsequent postoperative infectious complications after colorectal cancer surgery: a double-center and double-blind randomized clinical trial Am J Clin Nutr 2013 97 117 126 10.3945/ajcn.112.04094923235200 Search in Google Scholar

[94] McKenna LB, Schug J, Vourekas A, McKenna JB, Bramswig NC, Friedman JR, Kaestner KH. MicroRNAs control intestinal epithelial differentiation, architecture, and barrier function. Gastroenterology. 2010; 139: 1654–1664. McKennaLB SchugJ VourekasA McKennaJB BramswigNC FriedmanJR KaestnerKH MicroRNAs control intestinal epithelial differentiation, architecture, and barrier function Gastroenterology 2010 139 1654 1664 10.1053/j.gastro.2010.07.040315609720659473 Search in Google Scholar

[95] Wang D, Wang X, Tong W, Cui Y, Li X, Sun H. Umbelliferone alleviates lipopolysaccharide-induced inflammatory responses in acute lung injury by down-regulating TLR4/MyD88/NF-κB signaling. Inflammation. 2019; 42: 440–448. WangD WangX TongW CuiY LiX SunH Umbelliferone alleviates lipopolysaccharide-induced inflammatory responses in acute lung injury by down-regulating TLR4/MyD88/NF-κB signaling Inflammation 2019 42 440 448 10.1007/s10753-018-00953-430645708 Search in Google Scholar

[96] Kamba A, Lee I-A, Mizoguchi E. Potential association between TLR4 and chitinase 3-like 1 (CHI3L1/YKL-40) signaling on colonic epithelial cells in inflammatory bowel disease and colitis-associated cancer. Curr Mol Med. 2013; 13: 1110–1121. KambaA LeeI-A MizoguchiE Potential association between TLR4 and chitinase 3-like 1 (CHI3L1/YKL-40) signaling on colonic epithelial cells in inflammatory bowel disease and colitis-associated cancer Curr Mol Med 2013 13 1110 1121 10.2174/1566524011313070006366170623170831 Search in Google Scholar

[97] Wang H, Gu J, Hou X, Chen J, Yang N, Liu Y, Wang G, Du M, Qiu H, Luo Y, et al. Anti-inflammatory effect of miltirone on inflammatory bowel disease via TLR4/NF-κB/IQGAP2 signaling pathway. Biomed Pharmacother Biomedecine Pharmacother. 2017; 85: 531–540. WangH GuJ HouX ChenJ YangN LiuY WangG DuM QiuH LuoY Anti-inflammatory effect of miltirone on inflammatory bowel disease via TLR4/NF-κB/IQGAP2 signaling pathway Biomed Pharmacother Biomedecine Pharmacother 2017 85 531 540 10.1016/j.biopha.2016.11.06127903427 Search in Google Scholar

[98] Wu C-P, Bi Y-J, Liu D-M, Wang L-Y. Hsa-miR-375 promotes the progression of inflammatory bowel disease by upregulating TLR4. Eur Rev Med Pharmacol Sci. 2019; 23: 7543–7549. WuC-P BiY-J LiuD-M WangL-Y Hsa-miR-375 promotes the progression of inflammatory bowel disease by upregulating TLR4 Eur Rev Med Pharmacol Sci 2019 23 7543 7549 Search in Google Scholar

[99] Nunbhakdi-Craig V, Machleidt T, Ogris E, Bellotto D, White CL, Sontag E. Protein phosphatase 2A associates with and regulates atypical PKC and the epithelial tight junction complex. J Cell Biol. 2002; 158: 967–978. Nunbhakdi-CraigV MachleidtT OgrisE BellottoD WhiteCL SontagE Protein phosphatase 2A associates with and regulates atypical PKC and the epithelial tight junction complex J Cell Biol 2002 158 967 978 10.1083/jcb.200206114217315412196510 Search in Google Scholar

[100] Iden S, Misselwitz S, Peddibhotla SSD, Tuncay H, Rehder D, Gerke V, Robenek H, Suzuki A, Ebnet K. aPKC phosphorylates JAM-A at Ser285 to promote cell contact maturation and tight junction formation. J Cell Biol. 2012; 196: 623–639. IdenS MisselwitzS PeddibhotlaSSD TuncayH RehderD GerkeV RobenekH SuzukiA EbnetK aPKC phosphorylates JAM-A at Ser285 to promote cell contact maturation and tight junction formation J Cell Biol 2012 196 623 639 10.1083/jcb.201104143330769222371556 Search in Google Scholar

[101] Jaffe AB, Kaji N, Durgan J, Hall A. Cdc42 controls spindle orientation to position the apical surface during epithelial morphogenesis. J Cell Biol. 2008; 183: 625–633. JaffeAB KajiN DurganJ HallA Cdc42 controls spindle orientation to position the apical surface during epithelial morphogenesis J Cell Biol 2008 183 625 633 10.1083/jcb.200807121258289519001128 Search in Google Scholar

[102] Jin D, Durgan J, Hall A. Functional cross-talk between Cdc42 and two downstream targets, Par6B and PAK4. Biochem J. 2015; 467: 293–302. JinD DurganJ HallA Functional cross-talk between Cdc42 and two downstream targets, Par6B and PAK4 Biochem J 2015 467 293 302 10.1042/BJ2014135225662318 Search in Google Scholar

[103] Schlegel N, Meir M, Spindler V, Germer C-T, Waschke J. Differential role of Rho GTPases in intestinal epithelial barrier regulation in vitro. J Cell Physiol. 2011; 226: 1196–1203. SchlegelN MeirM SpindlerV GermerC-T WaschkeJ Differential role of Rho GTPases in intestinal epithelial barrier regulation in vitro J Cell Physiol 2011 226 1196 1203 10.1002/jcp.2244620945370 Search in Google Scholar

[104] Mehta S, Nijhuis A, Kumagai T, Lindsay J, Silver A. Defects in the adherens junction complex (E-cadherin/β-catenin) in inflammatory bowel disease. Cell Tissue Res. 2015; 360: 749–760. MehtaS NijhuisA KumagaiT LindsayJ SilverA Defects in the adherens junction complex (E-cadherin/β-catenin) in inflammatory bowel disease Cell Tissue Res 2015 360 749 760 10.1007/s00441-014-1994-625238996 Search in Google Scholar

[105] Veltman K, Hummel S, Cichon C, Sonnenborn U, Schmidt MA. Identification of specific miRNAs targeting proteins of the apical junctional complex that simulate the probiotic effect of E. coli Nissle 1917 on T84 epithelial cells. Int J Biochem Cell Biol. 2012; 44: 341–349. VeltmanK HummelS CichonC SonnenbornU SchmidtMA Identification of specific miRNAs targeting proteins of the apical junctional complex that simulate the probiotic effect of E. coli Nissle 1917 on T84 epithelial cells Int J Biochem Cell Biol 2012 44 341 349 10.1016/j.biocel.2011.11.00622101077 Search in Google Scholar

[106] Cordes F, Brückner M, Lenz P, Veltman K, Glauben R, Siegmund B, Hengst K, Schmidt MA, Cichon C, Bettenworth D. MicroRNA-320a strengthens intestinal barrier function and follows the course of experimental colitis. Inflamm Bowel Dis. 2016; 22: 2341–2355. CordesF BrücknerM LenzP VeltmanK GlaubenR SiegmundB HengstK SchmidtMA CichonC BettenworthD MicroRNA-320a strengthens intestinal barrier function and follows the course of experimental colitis Inflamm Bowel Dis 2016 22 2341 2355 10.1097/MIB.000000000000091727607334 Search in Google Scholar

[107] Wehkamp J, Götz M, Herrlinger K, Steurer W, Stange EF. Inflammatory bowel disease. Dtsch Arzteblatt Int. 2016; 113: 72–82. WehkampJ GötzM HerrlingerK SteurerW StangeEF Inflammatory bowel disease Dtsch Arzteblatt Int 2016 113 72 82 Search in Google Scholar

[108] Renna S, Cottone M, Orlando A. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. World J Gastroenterol. 2014; 20: 9675–9690. RennaS CottoneM OrlandoA Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease World J Gastroenterol 2014 20 9675 9690 10.3748/wjg.v20.i29.9675412335825110407 Search in Google Scholar

[109] Berg DR, Colombel J-F, Ungaro R. The role of early biologic therapy in inflammatory bowel disease. Inflamm Bowel Dis. 2019; 25: 1896–1905. BergDR ColombelJ-F UngaroR The role of early biologic therapy in inflammatory bowel disease Inflamm Bowel Dis 2019 25 1896 1905 10.1093/ibd/izz059718569030934053 Search in Google Scholar

[110] Kato T, Honda Y, Kurita Y, Iwasaki A, Sato T, Kessoku T, Uchiyama S, Ogawa Y, Ohkubo H, Higurashi T, et al. Lubiprostone improves intestinal permeability in humans, a novel therapy for the leaky gut: A prospective randomized pilot study in healthy volunteers. PLoS One. 2017; 12: e0175626. KatoT HondaY KuritaY IwasakiA SatoT KessokuT UchiyamaS OgawaY OhkuboH HigurashiT Lubiprostone improves intestinal permeability in humans, a novel therapy for the leaky gut: A prospective randomized pilot study in healthy volunteers PLoS One 2017 12 e0175626 10.1371/journal.pone.0175626539196128410406 Search in Google Scholar

[111] Craven L, Rahman A, Nair Parvathy S, Beaton M, Silverman J, Qumosani K, Hramiak I, Hegele R, Joy T, Meddings J, et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: A randomized control trial. Am J Gastroenterol. 2020; 115: 1055–1065. CravenL RahmanA Nair ParvathyS BeatonM SilvermanJ QumosaniK HramiakI HegeleR JoyT MeddingsJ Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: A randomized control trial Am J Gastroenterol 2020 115 1055 1065 10.14309/ajg.000000000000066132618656 Search in Google Scholar

[112] Yu A-M, Choi YH, Tu M-J. RNA drugs and RNA targets for small molecules: Principles, progress, and challenges. Pharmacol Rev. 2020; 72: 862–898. YuA-M ChoiYH TuM-J RNA drugs and RNA targets for small molecules: Principles, progress, and challenges Pharmacol Rev 2020 72 862 898 10.1124/pr.120.019554749534132929000 Search in Google Scholar

[113] Baek J, Kang S, Min H. MicroRNA-targeting therapeutics for hepatitis C. Arch Pharm Res. 2014; 37: 299–305. BaekJ KangS MinH MicroRNA-targeting therapeutics for hepatitis C Arch Pharm Res 2014 37 299 305 10.1007/s12272-013-0318-924385319 Search in Google Scholar

[114] Janssen HLA, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013; 368: 1685–1694. JanssenHLA ReesinkHW LawitzEJ ZeuzemS Rodriguez-TorresM PatelK van der MeerAJ PatickAK ChenA ZhouY Treatment of HCV infection by targeting microRNA N Engl J Med 2013 368 1685 1694 10.1056/NEJMoa120902623534542 Search in Google Scholar

[115] Lindow M, Kauppinen S. Discovering the first microRNA-targeted drug. J Cell Biol. 2012; 199: 407–412. LindowM KauppinenS Discovering the first microRNA-targeted drug J Cell Biol 2012 199 407 412 10.1083/jcb.201208082348312823109665 Search in Google Scholar

[116] Gallant-Behm CL, Piper J, Lynch JM, Seto AG, Hong SJ, Mustoe TA, Maari C, Pestano LA, Dalby CM, Jackson AL, et al. A microRNA-29 mimic (remlarsen) represses extracellular matrix expression and fibroplasia in the skin. J Invest Dermatol. 2019; 139: 1073–1081. Gallant-BehmCL PiperJ LynchJM SetoAG HongSJ MustoeTA MaariC PestanoLA DalbyCM JacksonAL A microRNA-29 mimic (remlarsen) represses extracellular matrix expression and fibroplasia in the skin J Invest Dermatol 2019 139 1073 1081 10.1016/j.jid.2018.11.00730472058 Search in Google Scholar

[117] Gomez IG, MacKenna DA, Johnson BG, Kaimal V, Roach AM, Ren S, Nakagawa N, Xin C, Newitt R, Pandya S, et al. Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. J Clin Invest. 2015; 125: 141–156. GomezIG MacKennaDA JohnsonBG KaimalV RoachAM RenS NakagawaN XinC NewittR PandyaS Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways J Clin Invest 2015 125 141 156 10.1172/JCI75852438224625415439 Search in Google Scholar

[118] Seto AG, Beatty X, Lynch JM, Hermreck M, Tetzlaff M, Duvic M, Jackson AL. Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. Br J Haematol. 2018; 183: 428–444. SetoAG BeattyX LynchJM HermreckM TetzlaffM DuvicM JacksonAL Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma Br J Haematol 2018 183 428 444 10.1111/bjh.1554730125933 Search in Google Scholar

[119] van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, Huynh Y, Chrzanowska A, Fulham MJ, Bailey DL, et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: A first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017; 18: 1386–1396. van ZandwijkN PavlakisN KaoSC LintonA BoyerMJ ClarkeS HuynhY ChrzanowskaA FulhamMJ BaileyDL Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: A first-in-man, phase 1, open-label, dose-escalation study Lancet Oncol 2017 18 1386 1396 10.1016/S1470-2045(17)30621-628870611 Search in Google Scholar

[120] Bonneau E, Neveu B, Kostantin E, Tsongalis GJ, De Guire V. How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market. EJIFCC. 2019; 30: 114–127. BonneauE NeveuB KostantinE TsongalisGJ De GuireV How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market EJIFCC 2019 30 114 127 Search in Google Scholar

[121] Vautrin A, Manchon L, Garcel A, Campos N, Lapasset L, Laaref AM, Bruno R, Gislard M, Dubois E, Scherrer D, et al. Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing. Sci Rep. 2019; 9: 792. VautrinA ManchonL GarcelA CamposN LapassetL LaarefAM BrunoR GislardM DuboisE ScherrerD Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing Sci Rep 2019 9 792 10.1038/s41598-018-37813-y634985730692590 Search in Google Scholar

[122] Tazi J, Begon-Pescia C, Campos N, Apolit C, Garcel A, Scherrer D. Specific and selective induction of miR-124 in immune cells by the quinoline ABX464: a transformative therapy for inflammatory diseases. Drug Discov Today. 2021; 26: 1030–1039. TaziJ Begon-PesciaC CamposN ApolitC GarcelA ScherrerD Specific and selective induction of miR-124 in immune cells by the quinoline ABX464: a transformative therapy for inflammatory diseases Drug Discov Today 2021 26 1030 1039 10.1016/j.drudis.2020.12.01933387693 Search in Google Scholar

[123] Vermeire S, Hébuterne X, Napora P, Wisniewska-Jarosinska M, Kiss G, Bourreille A, Przemysław Z, Nitcheu J, Gineste P, Steens J-M, et al. OP21 ABX464 is safe and efficacious in a proof-of-concept study in ulcerative colitis patients. J Crohns Colitis. 2019; 13: S014–S015. VermeireS HébuterneX NaporaP Wisniewska-JarosinskaM KissG BourreilleA PrzemysławZ NitcheuJ GinesteP SteensJ-M OP21 ABX464 is safe and efficacious in a proof-of-concept study in ulcerative colitis patients J Crohns Colitis 2019 13 S014 S015 10.1093/ecco-jcc/jjy222.020 Search in Google Scholar

[124] Vermeire S, Hébuterne X, Tilg H, De Hertogh G, Gineste P, Steens J-M. Induction and long-term follow-up with ABX464 for moderate-to-severe ulcerative colitis: Results of phase IIa trial. Gastroenterology. 2021; 160: 2595–2598.e3. VermeireS HébuterneX TilgH De HertoghG GinesteP SteensJ-M Induction and long-term follow-up with ABX464 for moderate-to-severe ulcerative colitis: Results of phase IIa trial Gastroenterology 2021 160 2595 2598.e3 10.1053/j.gastro.2021.02.05433662385 Search in Google Scholar